Skip to main content

Table 3 Adverse event requiring TMP-SMX discontinuation

From: Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study

Adverse event Low-dose
group (n = 36)
Standard-dose
group (n = 45)
Number of discontinued patients, n (%) 3 (8.3) 13 (28.9)
Details of adverse events
 Fever, n (%) 0 (0.0) 5 (11.1)
 Rash, n (%) 0 (0.0) 6 (13.3)
 Anorexia, n (%) 0 (0.0) 2 (4.4)
 Thrombocytopenia, n (%) 3 (8.3) 6 (13.3)
 Leukocytopenia, n (%) 3 (8.3) 2 (4.4)
 Anemia, n (%) 2 (5.6) 6 (13.3)
 Hyperkalemia, n (%) 1 (2.8) 2 (4.5)
 Hyponatremia, n (%) 2 (5.6) 6 (13.3)
 Increased alanine aminotransferase, n (%) 0 (0.0) 5 (11.1)
 Increased aspartate aminotransferase, n (%) 0 (0.0) 5 (11.1)
  1. The number of patients who discontinued due to adverse events and details of adverse events reported in each group are shown. Thirteen patients in the standard-dose group and three patients in the low-dose group discontinued TMP-SMX due to adverse events. Some patients experienced multiple adverse events
  2. Abbreviation: TMP-SMX trimethoprim-sulfamethoxazole